Category Archives: Recent Investment

SWAN is pleased to announce an investment in Vessl Prosthetics, which creates affordable, adaptive prosthetic sockets that automatically adjust to limb changes, offering bionic-level functionality and greater comfort for wearers.

Vessl has developed a new prosthetic socket designed specifically for amputees who have struggled to find a good fit with traditional sockets or who have felt that affordable options were not available to them. Vessl’s socket is the only socket that automatically adjusts as amputees’ legs change size. Custom panels maintain a consistent, clinician-set level of pressure on the leg even as the leg shrinks and swells. This socket is compatible with standard connectors, so prosthetists can easily integrate the Vessl socket with any shank and foot they choose. Vessl’s socket can be worn every day without pain or the need for prosthetic socks.

SWAN is pleased to announce an investment in AGED Diagnostics, which is using genomic innovation to develop the most accurate blood test for liver disease to help physicians keep patients in the monitoring program, reduce the financial burden for health insurers, and improve patient outcomes through early detection and intervention.

AGED tools can differentiate benign from advanced liver disease and simultaneously stage fibrosis (liver scarring). Their technology uses a targeted genomic sequencing assessment to measure the concentration of target biomarkers (genetic signatures) in circulation. The presence of biomarkers past a defined concentration indicates a diagnosis of liver disease (NASH) and/or fibrosis.

SWAN is pleased to announce an investment in Skope, a medical device company that manufactures a proprietary stethoscope disinfection technology to help simply and effectively reduce the chance of infections.

The Skope Station is a wall-mounted point-of-care device equipped with a disposable cartridge filled with an EPA-approved disinfectant. It swiftly eliminates infectious organisms, including Covid-19, bacterial spores, and MRSA, from a stethoscope’s diaphragm in one swipe, minimizing workflow disruption.

SWAN Impact Network is pleased to announce a follow-on investment in Eisana.

Eisana is an oncology solution company providing a platform for multiple products to address cancer treatment issues, including a patent-pending, cryo-compression device for hands and feet to wear before, during, and after infusion to prevent chemotherapy-induced peripheral neuropathy.

They are also developing a patent pending, state-of-the-art scalp cooling device to wear before, during, and after infusion to prevent chemotherapy-induced hair loss. The device is portable and can cool for long periods of time, necessary to have success even for drugs that take longer to leave the body.

SWAN previously invested in the company earlier in 2023.